VVUS Related Earnings News
-
UPDATE: Lazard Capital Downgrades Vivus (VVUS) to Neutral
-
Brean Capital Maintains Sell of Vivus (VVUS), Notes Slower April Growth
-
VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
-
VIVUS, Inc. (VVUS) Posts Q1 Loss of 53c/Share
-
VIVUS (VVUS) to Report Q1 Results May 8th; Focus on Promotions vs. New Rx
-
VIVUS (VVUS) Inks Qsymia Deal with MEDCO; 'Executing Well' Says Analyst
-
Leerink Swann Reiterates Outperform on VIVUS (VVUS), Review in Health Economics A Positive
-
Vivus (VVUS) Financing Agreement Does Not Appear Cheap - Analyst
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
VIVUS, Inc. (VVUS) Misses Q4 Views on Heftier Qsymia Costs; Analysts Comment
-
Needham & Company Sees 2nd-Half Qsymia Ramp for Vivus (VVUS)
-
UPDATE: VIVUS, Inc. (VVUS) Posts Q4 Loss of 56c/Share
-
Despite Slow Launch, Vivus's (VVUS) Qsymia Still Has Blockbuster Potential
-
Jefferies Slashes Numbers on Vivus (VVUS) on Slow Qsymia Uptake; Sees Another 45% Downside
-
Needham & Company Cuts Numbers on VIVUS Inc. (VVUS) on Slower Qsymia Launch, Keeps Buy on Blockbuster Potential
-
VIVUS (VVUS) Sell Off Overdone; Wells Says All Drugs Have Abandonment, Co-Pay Issues
-
VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay
-
VIVUS (VVUS) Ticks Lower; Wider Q3 Loss Attributed to Qsymia Launch, Expansion (ARNA) (OREX)
-
VIVUS, Inc. (VVUS) Posts Wider than Expected Q3 Loss of 40c/Share
-
Obesity Pill Pharma Gear Up to Report Q3 Results Next Week (ARNA) (OREX) (VVUS)
-
Are Obesity Pills Hammering the Nail in Weight Watchers' (WTW) Coffin? Maybe Not...
-
Brean Murray Carret & Co. Downgrades Vivus (VVUS); Qsymia Approval Huge, But Struggling with Valuation Until Launch Proves Otherwise
-
Vivus, Inc. (VVUS) Misses Q1 EPS by 7c
-
Jefferies Bumps Price Target on VIVUS (VVUS) Following Q4, Keeps Underperform Rating
-
Vivus, Inc. (VVUS) Reports Wider than Expected Operating Loss of 14c/Share
-
Leerink Swann Upgrades Vivus (VVUS) to Outperform; Becoming A More Attractive Asset For Big Pharma After Qnexa Approval
-
Vivus, Inc. (VVUS) Posts Q3 Loss of 10c/Share
-
Vivus, Inc. (VVUS) Posts Q2 EPS Loss of $0.20
-
VIVUS Inc. (VVUS) Reports Q1 Loss of $0.12/Share
-
VIVUS Inc. (VVUS) Misses Q4 EPS by 1c
-
Vivus (VVUS) Posts Q3 Loss of $0.22, Narrower than Views
-
Vivus (VVUS) Posts Q2 Loss of $0.28, Misses Views
-
Vivus (VVUS) Q1 Loss Smaller by 3c
-
Vivus (VVUS) Posts Narrower than Expected Q4 Loss of $0.16
-
Vivus (VVUS) Posts Q3 Loss of $0.30, Tops by 1c
-
VIVUS (VVUS) Reports Better-Than-Expected Q2 Loss of $0.19
-
Vivus (VVUS) Reports Q1 Loss of $0.10, Misses by 3c
-
Vivus (VVUS) Reports Mixed Q4 Results
-
Vivus (VVUS) Reports Breakeven Q3 Earnings
-
VIVUS (VVUS) Tops Q2 View
-
Vivus (VVUS) Reports Q1 Loss of $0.12
-
Vivus (VVUS) Misses By 3c
-
VIVUS, Inc. (VVUS) Tops Q4 EPS by 7c
-
Earnings Due Out After The Close Today
Back to VVUS Stock Lookup
